vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and TOMPKINS FINANCIAL CORP (TMP). Click either name above to swap in a different company.
TOMPKINS FINANCIAL CORP is the larger business by last-quarter revenue ($194.8M vs $183.1M, roughly 1.1× Amphastar Pharmaceuticals, Inc.). TOMPKINS FINANCIAL CORP runs the higher net margin — 49.4% vs 13.3%, a 36.1% gap on every dollar of revenue. On growth, TOMPKINS FINANCIAL CORP posted the faster year-over-year revenue change (152.7% vs -1.8%). TOMPKINS FINANCIAL CORP produced more free cash flow last quarter ($31.9M vs $24.6M). Over the past eight quarters, TOMPKINS FINANCIAL CORP's revenue compounded faster (63.6% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Tompkins Financial Corporation is a small, diversified financial services company based in Ithaca, New York. It is the parent of the Tompkins Trust Company, as well as several other banks, an insurance agency, and a wealth management division.
AMPH vs TMP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $194.8M |
| Net Profit | $24.4M | $96.2M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 71.7% |
| Net Margin | 13.3% | 49.4% |
| Revenue YoY | -1.8% | 152.7% |
| Net Profit YoY | -35.7% | 388.9% |
| EPS (diluted) | $0.51 | $6.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $194.8M | ||
| Q3 25 | $191.8M | $87.4M | ||
| Q2 25 | $174.4M | $82.6M | ||
| Q1 25 | $170.5M | $81.7M | ||
| Q4 24 | $186.5M | $77.1M | ||
| Q3 24 | $191.2M | $76.6M | ||
| Q2 24 | $182.4M | $72.7M | ||
| Q1 24 | $171.8M | $72.8M |
| Q4 25 | $24.4M | $96.2M | ||
| Q3 25 | $17.4M | $23.7M | ||
| Q2 25 | $31.0M | $21.5M | ||
| Q1 25 | $25.3M | $19.7M | ||
| Q4 24 | $38.0M | $19.7M | ||
| Q3 24 | $40.4M | $18.6M | ||
| Q2 24 | $37.9M | $15.7M | ||
| Q1 24 | $43.2M | $16.9M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 71.7% | ||
| Q3 25 | 13.2% | 35.6% | ||
| Q2 25 | 24.2% | 34.2% | ||
| Q1 25 | 21.9% | 31.6% | ||
| Q4 24 | 24.2% | 33.4% | ||
| Q3 24 | 29.8% | 32.0% | ||
| Q2 24 | 30.3% | 28.3% | ||
| Q1 24 | 27.9% | 30.4% |
| Q4 25 | 13.3% | 49.4% | ||
| Q3 25 | 9.0% | 27.1% | ||
| Q2 25 | 17.8% | 26.0% | ||
| Q1 25 | 14.8% | 24.1% | ||
| Q4 24 | 20.4% | 25.5% | ||
| Q3 24 | 21.1% | 24.3% | ||
| Q2 24 | 20.8% | 21.6% | ||
| Q1 24 | 25.1% | 23.2% |
| Q4 25 | $0.51 | $6.72 | ||
| Q3 25 | $0.37 | $1.65 | ||
| Q2 25 | $0.64 | $1.50 | ||
| Q1 25 | $0.51 | $1.37 | ||
| Q4 24 | $0.74 | $1.39 | ||
| Q3 24 | $0.78 | $1.30 | ||
| Q2 24 | $0.73 | $1.10 | ||
| Q1 24 | $0.81 | $1.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $132.8M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $938.4M |
| Total Assets | $1.6B | $8.7B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $132.8M | ||
| Q3 25 | $276.2M | $193.5M | ||
| Q2 25 | $231.8M | $212.6M | ||
| Q1 25 | $236.9M | $193.1M | ||
| Q4 24 | $221.6M | $134.4M | ||
| Q3 24 | $250.5M | $132.3M | ||
| Q2 24 | $217.8M | $70.9M | ||
| Q1 24 | $289.6M | $57.1M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $938.4M | ||
| Q3 25 | $776.7M | $788.8M | ||
| Q2 25 | $757.5M | $761.8M | ||
| Q1 25 | $751.3M | $741.4M | ||
| Q4 24 | $732.3M | $713.4M | ||
| Q3 24 | $727.7M | $719.9M | ||
| Q2 24 | $713.3M | $674.6M | ||
| Q1 24 | $672.4M | $667.9M |
| Q4 25 | $1.6B | $8.7B | ||
| Q3 25 | $1.7B | $8.5B | ||
| Q2 25 | $1.6B | $8.4B | ||
| Q1 25 | $1.6B | $8.2B | ||
| Q4 24 | $1.6B | $8.1B | ||
| Q3 24 | $1.5B | $8.0B | ||
| Q2 24 | $1.5B | $7.9B | ||
| Q1 24 | $1.6B | $7.8B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $38.9M |
| Free Cash FlowOCF − Capex | $24.6M | $31.9M |
| FCF MarginFCF / Revenue | 13.4% | 16.4% |
| Capex IntensityCapex / Revenue | 4.5% | 3.6% |
| Cash ConversionOCF / Net Profit | 1.35× | 0.40× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $105.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $38.9M | ||
| Q3 25 | $52.6M | $34.9M | ||
| Q2 25 | $35.6M | $18.9M | ||
| Q1 25 | $35.1M | $22.2M | ||
| Q4 24 | $29.0M | $95.0M | ||
| Q3 24 | $60.0M | $21.2M | ||
| Q2 24 | $69.1M | $27.3M | ||
| Q1 24 | $55.3M | $23.2M |
| Q4 25 | $24.6M | $31.9M | ||
| Q3 25 | $47.2M | $33.9M | ||
| Q2 25 | $25.0M | $18.3M | ||
| Q1 25 | $24.4M | $20.9M | ||
| Q4 24 | $16.6M | $88.8M | ||
| Q3 24 | $46.2M | $18.9M | ||
| Q2 24 | $63.1M | $26.3M | ||
| Q1 24 | $46.5M | $21.9M |
| Q4 25 | 13.4% | 16.4% | ||
| Q3 25 | 24.6% | 38.8% | ||
| Q2 25 | 14.3% | 22.1% | ||
| Q1 25 | 14.3% | 25.5% | ||
| Q4 24 | 8.9% | 115.1% | ||
| Q3 24 | 24.1% | 24.7% | ||
| Q2 24 | 34.6% | 36.2% | ||
| Q1 24 | 27.1% | 30.0% |
| Q4 25 | 4.5% | 3.6% | ||
| Q3 25 | 2.8% | 1.1% | ||
| Q2 25 | 6.1% | 0.8% | ||
| Q1 25 | 6.3% | 1.7% | ||
| Q4 24 | 6.7% | 8.1% | ||
| Q3 24 | 7.2% | 2.9% | ||
| Q2 24 | 3.3% | 1.3% | ||
| Q1 24 | 5.1% | 1.9% |
| Q4 25 | 1.35× | 0.40× | ||
| Q3 25 | 3.03× | 1.47× | ||
| Q2 25 | 1.15× | 0.88× | ||
| Q1 25 | 1.39× | 1.13× | ||
| Q4 24 | 0.76× | 4.82× | ||
| Q3 24 | 1.48× | 1.14× | ||
| Q2 24 | 1.82× | 1.74× | ||
| Q1 24 | 1.28× | 1.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
TMP
Segment breakdown not available.
